VASN and hepatocellular carcinoma: Higher VASN levels were verified in HCC serum compared with that in control cohorts, with an AUROC of 0.770, sensitivity of 69%, and specificity of 80.5% for the diagnosis of HCC; VASN was positive in 62% (23/37) of ANHC cases, indicating that VASN may be a potential biomarker for HCC diagnosis (138).